Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications

Authors: Cuilan Li, Vincent WS Liu, Pui M Chiu, David W Chan, Hextan YS Ngan

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

AMP-activated protein kinase (AMPK) has recently been considered as a potential target for cancer therapy. However, the expression status of various subunits of the heterotrimeric AMPK in human cancers is rarely reported. We decided to determine their expressions in ovarian carcinomas and their relationships with the disease.

Methods

Expressions and locations of the AMPK-α1, -α2, -β1, -β2, -γ1 and -γ2 were detected by quantitative PCR (Q-PCR) and immunohistochemical staining (IHC). Their expression levels in ovarian tumors were compared with normal controls and also correlated with clinicopathological parameters.

Results

Except AMPK-α1, expressions of the other five AMPK subunits are significantly higher in ovarian carcinomas as determined by Q-PCR. Although IHC detection of AMPK-γ1 and -γ2 were not successful, over-expressions of AMPK-α2, -β1, and -β2 were further confirmed by IHC. Over-expressions of various AMPK subunits occurred independently and were mainly detected in the cytoplasm. Interestingly, AMPK-α2 and -β1 were also detected in the nucleus and cell membrane, respectively. Clinical correlation analyses indicate that expressions of different AMPK subunits are associated with different subtypes of carcinoma. High expression of AMPK-α2 is significantly associated with endometrioid carcinomas. On the other hand, high expressions of AMPK-β and -γ subunits are associated with mucinous and serous carcinomas, respectively. Furthermore, high expressions of AMPK-β1 and -γ2 are also associated with early and late stages of disease, respectively. Finally, patients with high expression of AMPK-α2 had better prognosis.

Conclusions

Aberrant expressions of AMPK subunits may play important roles in ovarian carcinogenesis. Each AMPK subunit may have its own function other than just a component of the AMPK molecule. Correlations with clinical parameters suggest that expressions of AMPK subunits have different clinical implications in ovarian cancer development.
Appendix
Available only for authorised users
Literature
1.
Hardie DG: AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007, 8: 774-785. 10.1038/nrm2249.CrossRefPubMed
2.
Steinberg GR, Kemp BE: AMPK in Health and Disease. Physiol Rev. 2009, 89: 1025-1078. 10.1152/physrev.00011.2008.CrossRefPubMed
3.
Shackelford DB, Shaw RJ: The LKB1–AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009, 9: 563-575. 10.1038/nrc2676.CrossRefPubMedPubMedCentral
4.
Fogarty S, Hardie DG: Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta. 2010, 1804: 581-591. 10.1016/j.bbapap.2009.09.012.CrossRefPubMed
5.
Yu SY, Chan DW, Liu VW, Ngan HY: Inhibition of cervical cancer cell growth through activation of upstream kinases of AMP-activated protein kinase. Tumour Biol. 2009, 30: 80-85. 10.1159/000216843.CrossRefPubMed
6.
Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I: In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 2008, 110: 246-250. 10.1016/j.ygyno.2008.04.008.CrossRefPubMed
7.
Rattan R, Giri S, Hartmann LC, Shridhar V: Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med. 2011, 15: 166-178. 10.1111/j.1582-4934.2009.00954.x.CrossRefPubMed
8.
Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M, Gotlieb WH: Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins. Gynecol Oncol. 2011, 121: 492-498. 10.1016/j.ygyno.2011.02.021.CrossRefPubMed
9.
Brenman JE: AMPK/LKB1 signaling in epithelial cell polarity and cell division. Cell Cycle. 2007, 6: 2755-2759. 10.4161/cc.6.22.4927.CrossRefPubMed
10.
Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008, 3: 1101-1108. 10.1038/nprot.2008.73.CrossRefPubMed
11.
Huang FY, Chiu PM, Tam KF, Kwok YK, Lau ET, Tang MH, Ng TY, Liu VW, Cheung AN, Ngan HY: Semi-quantitative fluorescent PCR analysis identifies PRKAA1 on chromosome 5 as a potential candidate cancer gene of cervical cancer. Gynecol Oncol. 2006, 103: 219-225. 10.1016/j.ygyno.2006.02.028.CrossRefPubMed
12.
Wang Y, Chan DW, Liu VW, Chiu PM, Ngan HY: Differential functions of growth factor receptor-bound protein 7 (GRB7) and its variant GRB7v in ovarian carcinogenesis. Clin Cancer Res. 2010, 16: 2529-2539. 10.1158/1078-0432.CCR-10-0018.CrossRefPubMed
13.
Hallstrom TC, Mori S, Nevins JR: An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell. 2008, 13: 11-22. 10.1016/j.ccr.2007.11.031.CrossRefPubMedPubMedCentral
14.
Neurath KM, Keough MP, Mikkelsen T, Claffey KP: AMP-dependent protein kinase alpha 2 isoform promotes hypoxia-induced VEGF expression in human glioblastoma. Glia. 2006, 53: 733-743. 10.1002/glia.20326.CrossRefPubMed
15.
Lee YG, Lee SW, Sin HS, Kim EJ, Um SJ: Kinase activity-independent suppression of p73alpha by AMP-activated kinase alpha (AMPKalpha). Oncogene. 2009, 28: 1040-1052. 10.1038/onc.2008.452.CrossRefPubMed
16.
Li J, Jiang P, Robinson M, Lawrence TS, Sun Y: AMPK-beta1 subunit is a p53-independent stress responsive protein that inhibits tumor cell growth upon forced expression. Carcinogenesis. 2003, 24: 827-834. 10.1093/carcin/bgg032.CrossRefPubMed
Metadata
Title
Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications
Authors
Cuilan Li
Vincent WS Liu
Pui M Chiu
David W Chan
Hextan YS Ngan
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-357

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

Adherence evaluation of endocrine treatment in breast cancer: methodological aspects

Research article

Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events

Research article

The TERT rs2736100 Polymorphism and Cancer Risk: A Meta-analysis Based on 25 Case-Control Studies

Research article

Preclinical evaluation of Gd-DTPA and gadomelitol as contrast agents in DCE-MRI of cervical carcinoma interstitial fluid pressure

Research article

Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines

Research article

Adeno-associated virus-mediated doxycycline-regulatable TRAIL expression suppresses growth of human breast carcinoma in nude mice
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits